149 related articles for article (PubMed ID: 36411451)
1. SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia.
Wu DL; Wang Y; Zhang TJ; Chu MQ; Xu ZJ; Yuan Q; Ma JC; Lin J; Qian J; Zhou JD
Eur J Med Res; 2022 Nov; 27(1):259. PubMed ID: 36411451
[TBL] [Abstract][Full Text] [Related]
2. SLIT2 promoter hypermethylation-mediated SLIT2-IT1/miR-218 repression drives leukemogenesis and predicts adverse prognosis in myelodysplastic neoplasm.
Zhang TJ; Xu ZJ; Wen XM; Gu Y; Ma JC; Yuan Q; Lin J; Zhou JD; Qian J
Leukemia; 2022 Oct; 36(10):2488-2498. PubMed ID: 35906386
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of DLX4 is associated with disease progression in chronic myeloid leukemia.
Zhou JD; Wang YX; Zhang TJ; Yang DQ; Yao DM; Guo H; Yang L; Ma JC; Wen XM; Yang J; Lin J; Qian J
Biochem Biophys Res Commun; 2015 Aug; 463(4):1250-6. PubMed ID: 26086097
[TBL] [Abstract][Full Text] [Related]
4. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
[TBL] [Abstract][Full Text] [Related]
5. [SHP-1 gene in the disease progression of chronic myeloid leukemia].
Li Y; Wang X; Yang L; Pan Y; Shang Y; Luo J
Zhonghua Xue Ye Xue Za Zhi; 2014 Dec; 35(12):1074-8. PubMed ID: 25543700
[TBL] [Abstract][Full Text] [Related]
6. Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia.
Li Y; Yang L; Pan Y; Yang J; Shang Y; Luo J
Oncol Rep; 2014 May; 31(5):2438-46. PubMed ID: 24647617
[TBL] [Abstract][Full Text] [Related]
7. [Methylation status of id4 gene promoter in patients with chronic myeloid leukemia].
Wang XR; Kang HY; Cen J; Li YH; Wang LL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1402-4. PubMed ID: 21176338
[TBL] [Abstract][Full Text] [Related]
8. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
[TBL] [Abstract][Full Text] [Related]
10. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
11. [Methylation of miR-378 in Chronic Myeloid Leukemia].
Wu DH; Yang J; Yang L; Wen XM; Guo H; Yao DM; Lin J; Zhang YY; Zhang M; Deng ZQ; Qian J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):61-5. PubMed ID: 26913395
[TBL] [Abstract][Full Text] [Related]
12. Methylation status of DDIT3 gene in chronic myeloid leukemia.
Wang YL; Qian J; Lin J; Yao DM; Qian Z; Zhu ZH; Li JY
J Exp Clin Cancer Res; 2010 May; 29(1):54. PubMed ID: 20492726
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia.
Qian J; Wang YL; Lin J; Yao DM; Xu WR; Wu CY
Eur J Haematol; 2009 Feb; 82(2):119-23. PubMed ID: 19018866
[TBL] [Abstract][Full Text] [Related]
14.
Zhang TJ; Wen XM; Zhou JD; Gu Y; Xu ZJ; Guo H; Ma JC; Yuan Q; Chen Q; Lin J; Qian J
Onco Targets Ther; 2019; 12():4789-4794. PubMed ID: 31417278
[TBL] [Abstract][Full Text] [Related]
15. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia.
Samaiya M; Bakhshi S; Shukla AA; Kumar L; Chauhan SS
J Cell Mol Med; 2011 Oct; 15(10):2189-99. PubMed ID: 21496199
[TBL] [Abstract][Full Text] [Related]
17. Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival.
Guru SA; Sumi MP; Mir R; Beg MMA; Koner BC; Saxena A
BMC Cancer; 2022 Apr; 22(1):405. PubMed ID: 35421941
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation of SLIT2 is a risk factor and potential diagnostic biomarker for nasopharyngeal carcinoma.
Li J; Zhou C; Wang G; Wang S; Ni S; Ye M; Zhang J
Gene; 2018 Feb; 644():74-79. PubMed ID: 29107007
[TBL] [Abstract][Full Text] [Related]
19. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia.
Asimakopoulos FA; Shteper PJ; Krichevsky S; Fibach E; Polliack A; Rachmilewitz E; Ben-Neriah Y; Ben-Yehuda D
Blood; 1999 Oct; 94(7):2452-60. PubMed ID: 10498618
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34
Maupetit-Mehouas S; Court F; Bourgne C; Guerci-Bresler A; Cony-Makhoul P; Johnson H; Etienne G; Rousselot P; Guyotat D; Janel A; Hermet E; Saugues S; Berger J; Arnaud P; Berger MG
Mol Oncol; 2018 Jun; 12(6):814-829. PubMed ID: 29575763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
